JP5739109B2 - Fig-derived anti-type I allergic agent and method for producing the same - Google Patents

Description

The present invention relates to an anti- type I allergy agent containing an extract component extracted from a fig plant as an anti- type I allergy active ingredient and a method for producing the same.

  In recent years, an increasing number of people show allergic symptoms such as hay fever, allergic rhinitis, food allergies, contact dermatitis, atopic dermatitis, bronchial asthma, and so on, which has become a major social problem. Allergy is an example of an excessive immune response and is classified as type I-IV. Allergic diseases such as hay fever and atopic dermatitis, which have a high social attention, are type I allergies.

Type I allergy develops in the following process.
(1) When an allergen such as pollen or mold that becomes an antigen invades into a living body, an IgE (immunoglobulin E) type antibody corresponding thereto is excessively produced from B cells.
(2) The prepared IgE antibody binds to the high affinity IgE receptor expressed on the surface of mast cells (also called mast cells) or basophil cells (sensitization), thereby preparing the allergic reaction (sensitivity). Work state).
(3) The allergen enters again and crosslinks IgE antibodies on the cell surface in the sensitized state (antigen-antibody reaction).
(4) Release of chemical mediators such as histamine and leukotriene (degranulation) occurs by the stimulation.
(5) The chemical mediator causes allergic symptoms such as inflammation and increased vascular permeability in surrounding tissues.

  In general, drugs such as antihistamines and steroids are administered to patients who develop such type I allergies. While these drugs are highly effective, side effects such as drowsiness, dry mouth and gastrointestinal disorders are problematic. In addition, in order to improve allergic symptoms, long-term medication is required, and therefore, an antiallergic agent that is highly safe for treatment and can be used continuously is desirable instead of a drug that may cause side effects. Naturally derived antiallergic agents are considered to be safer than the above drugs. For example, Patent Documents 1 to 6 report plant-derived antiallergic agents.

Patent Document 1 discloses that an extract of a genus Helichrysum has antiallergic effects such as interleukin 4 signaling inhibitory activity (IgE class switch inhibitory activity), FcεRI expression reducing activity, and histamine release inhibitory activity. It is described.
Patent Document 2 describes an antiallergic agent containing, as an active ingredient, an extract obtained by extraction from a plant of Momotamana or moon peach, or water or an organic solvent alone or a mixture thereof from the plant.
Patent Document 3 describes an antiallergic agent characterized by containing, as an active ingredient, an extract or extract obtained by extraction from a Citrurus plant with a lower aliphatic alcohol or a hydrated product thereof.
Patent Document 4 describes an antiallergic agent characterized by containing rice-derived polyphenol as an active ingredient.
Patent Document 5 is characterized by containing at least one of plant roses and rose extracts, and fermented products obtained by fermentation of these, and α-cyclodextrin. Antiallergic agents are described.
Patent Document 6 describes an antiallergic agent characterized by containing an active ingredient of purslane.

JP 2009-96761 A JP 2006-117562 A JP 2006-206520 A JP 2007-45755 A JP 2007-176797 A JP 2008-247779 A

In Patent Documents 1 to 6, antiallergic agents are prepared from various plants such as Helichrysum genus plants, Momotamana, Moon peach, Citrullus genus plants, rice, rose genus plants, and purslane. When preventing or treating allergic symptoms, not limited to type I allergies, it is desirable that the number of types of plants capable of producing anti-allergic agents that are highly safe and can be used continuously is as large as possible. Furthermore, it is desirable that such a plant-derived antiallergic agent is prepared for drinking, edible use, application, etc. so that it can be adapted to the tastes of the consumer, and can be easily ingested in as many different forms as possible.
In order to extract a component effective for allergy from a leaf of a plant, for example, the leaf of the plant is made and extracted with a solvent. By using the extract obtained at this time for drinking, an antiallergic agent containing an allergy effective component can be obtained.

  In drinking, leaves of trees other than tea trees are rarely used. For example, figs are only processed into drinking tea in a few areas except for eating fruit. For this reason, most of the parts other than the fruit have been discarded and are not effectively used. Fig leaves are known to contain functional components such as polyphenols, but the fig leaves have almost been discarded and research has not progressed, and many unidentified components are still included. It is thought that.

Accordingly, an object of the present invention is to provide a fig-derived anti- type I allergic agent that is highly safe and can be used continuously, and a method for producing the same.

In order to achieve the above object, the first characteristic configuration of the anti- type I allergic agent according to the present invention is that the extracted component extracted from the fig leaf with any extraction solvent of water, hot water, alcohol or hydrous alcohol is type I It exists in the point contained as an anti- type I allergy active ingredient with respect to allergy.

As a result of intensive studies, the present inventors have newly found that the fig leaf contains an anti- type I allergy active ingredient against type I allergy. If it is an anti- type I allergy agent of this composition, since it can serve as an anti- type I allergy agent which contains a plant-derived ingredient as an anti- type I allergy active ingredient, it is safe and can be used continuously.
In general, to suppress type I allergy, (1) suppress overproduction of antibody, (2) suppress sensitization, (3) suppress degranulation reaction, (4) allergic symptoms after degranulation, ie Possible measures include suppressing inflammation and edema. Among these, the existing antiallergic techniques are (3) and (4). In Example 1 described below, the fig tea extract has been found to suppress cell sensitization. That is, with the anti- type I allergic agent of the present invention, it is recognized that the symptoms of type I allergy can be suppressed by suppressing sensitization.

Moreover, according to this structure, in order to obtain the plant extraction composition containing these desired anti- type I allergy active ingredients, parts other than fruits, such as a fig leaf, can also be utilized. In view of the current situation where most of the parts other than the fruit are discarded, the fig plant can be used effectively.

When the extraction solvent is water and hot water, the anti- type I allergic agent can be obtained by a technique according to the general preparation of tea extract. Further, when the extraction solvent is alcohol or hydrous alcohol, an easily available organic solvent can be used as the extraction solvent.
Therefore, according to this structure, an anti- type I allergic agent can be obtained simply.

The second characteristic constitution of the anti- type I allergic agent according to the present invention is that the fig leaf is cooked with steam at 95 ° C. to 100 ° C. for 0.5 to 10 minutes, and the fig leaf subjected to the heat treatment is treated with tea leaf temperature. To the dried fig leaf, a fig process that abstains for 25 to 40 minutes at a temperature of 35 to 60 ° C, a fig leaf that has undergone the aide treatment is dried at 55 to 65 ° C for 2 to 5 hours, It is the point which contains the extraction component which added the hot water which is an extraction solvent and extracted at the temperature of 80-100 degreeC at 1 atmosphere as an anti- type I allergy active ingredient.

As in this configuration, heat treatment, acupuncture treatment, drying treatment and extraction treatment are performed, and the extraction solvent used for extraction is hot water, so that anti- type I allergy active ingredients can be easily used without using organic solvents. Can be extracted efficiently.

The third characteristic configuration of the anti- type I allergic agent according to the present invention lies in that the fig variety is any one of Sakurai Dauphin, Temari fig, Dalmaty, Precos Ronde de Bordeaux, and Negrone.

According to this configuration, since an easily available variety is used, an anti- I type allergic agent can be easily obtained.

A fourth characteristic configuration of the anti- type I allergy agent according to the present invention is that the anti- type I allergy active ingredient is formulated in the form of a solid preparation or a liquid preparation.

According to this configuration, it can be used as an antiallergic agent containing an anti- type I allergy active ingredient extracted from FIG. In addition, since the drug is formulated in the form of a solid preparation or a liquid preparation, it can be easily administered in both oral administration and parenteral administration.

The first characteristic configuration of the method for producing an anti- type I allergic agent according to the present invention is a heat treatment for steaming the fig leaf, an astringent treatment for abusing the fig leaf that has been subjected to the heat treatment, and the astringent treatment. In the point which performs the drying process which dries a fig leaf, the hot water which is an extraction solvent is added to the said dried fig leaf, and the extraction process which acquires the anti- type I allergy active ingredient with respect to a type I allergy is performed is there.

As in this configuration, heat treatment, acupuncture treatment, drying treatment and extraction treatment are performed, and the extraction solvent used for extraction is hot water, so that anti- type I allergy active ingredients can be easily used without using organic solvents. Can be extracted efficiently.

A second characteristic configuration of the method for producing an anti- type I allergic agent according to the present invention is that the heat treatment is performed with steam at 95 ° C. to 100 ° C. for 0.5 to 10 minutes, and the astringent treatment is performed at a tea leaf temperature of 35-60. In the state which becomes 25 degreeC, it is 25 to 40 minutes, The said drying process is performed for 2 to 5 hours at 55-65 degreeC, and the said extraction process exists in the point performed at the temperature of 80-100 degreeC by 1 atmosphere.

According to this configuration, it is possible to specify suitable temperature conditions for the heat treatment, the idea processing, and the drying treatment. Since these conditions are conditions that can be set using a general warming device, the anti- type I allergy active ingredient can be easily extracted.

It is a figure which shows the outline of the process process in the case of extracting an anti- type I allergic agent with hot water. It is a graph which shows the evaluation result of an antiallergic action. It is a graph which shows the evaluation result of the antiallergic action which several kinds of fig tea has. It is a graph which shows the evaluation result of the antiallergic action which each fraction collect | recovered by preparative HPLC has.

Embodiments of the present invention will be described below with reference to the drawings.
The present invention is an anti- type I allergic agent having an extract component derived from nature, particularly a plant, which can alleviate / suppress / prevent allergic symptoms and a method for producing the same.
Allergy is an example of an excessive immune reaction, and an anti-allergic action has been observed in plant-derived extract components. The anti- type I allergy agent of the present invention contains an extracted component extracted from a fig leaf with an extraction solvent as an anti- type I allergy active ingredient.
The present invention is particularly applicable to type I allergies such as hay fever and atopic dermatitis.

  Fig (Ficus carica L.) is a plant of the genus Figaceae. Figs include, for example, Masui Dauphine, which is a major cultivar in Japan, as well as Aida, Archipel, Adam, Athene, Adriano, and Abiko ( Abicou, Angelique, Excel, Kadota, California Black, Calimyrna, King, Goutte d'Or, Grease St. Grise de Saint-Jean, Grise de Tarascon, Conadria, Contessina, Sultane, Sugar, Short Bridge, Celeste ( Cereste, Dalmatie, Desert Queen, Tena, Panachee ), Daw Low, Dottato, Noir deCaromb, Negronne, Negro Largo, Nordland, Noir Sucre ), Pastiliere, Banane, Paradiso, Violette de Sollies, Violetta, Violette de Dauphine, Violette de Bordeaux , Figue de Marseilles, Brown Turkey, Black Jack, Black Mission, Bourjasotte Gris, Brunswick, Precoe Ronde de Bordeaux, Brogiotto Nero, Bro Brogiotto Bianco, Bellone, Houraishi, Peau Dure, Dell Portogallo, White Adriatic, White Ischia, White White Genoa, White Marseilles, Magnolia, Mission, Lisa, Reculver, Royal Vineyard, Rhodos, Long Doot (Longue d'Aout), early-stage dough (Wase Dauphine), etc. may be used, but are not limited thereto. Of these, Sakurai Dauphin, Temari Figs, Dalmaty, Precos Ronde de Bordeaux and Negrone are particularly preferred.

The fig plant used in the present invention may utilize leaves. Of the leaves, it is particularly preferable to use young leaves at the tip of the shoot. In the present specification, for example, the whole plant of fig or a part thereof is referred to as “plant”.
A new treetop is a newly grown branch, also called the current branch.
Wakaba refers to freshly grown leaves. For example, in the case of FIG., It is preferable to use the leaves from the tip of the new treetop to about the fifth node with about 14 days after the leaves emerge. When young leaves at the tip of the new tree are used, extraction with an extraction solvent is easy, and an anti- I-type allergic agent can be efficiently obtained.
The plant body may be raw or dry. The size of the plant used for extracting the antioxidant (the degree of pulverization) is not particularly limited. For example, a powder state to a rough cut state is preferable.

As the extraction solvent, water, hot water and an organic solvent may be used. Hot water is good to make it the temperature of 80-100 degreeC, for example at 1 atmosphere. When extracting with hot water, it can manufacture by the following methods.
That is, the heat treatment A for steaming the fig leaf, the remedy treatment B for devouring the fig leaf subjected to the heat treatment, the drying treatment C for drying the fig leaf devised, and the dried fig leaf with an extraction solvent A certain hot water is added and the extraction process D which acquires the extraction composition containing the anti- type I allergy active ingredient with respect to a type I allergy is performed (FIG. 1).

  The heat treatment is a treatment for inactivating the fig leaf enzyme by heat, for example, by exposing the fig leaf to water vapor at 100 ° C. The heating temperature is not limited to 100 ° C., as long as the enzyme is deactivated. For example, the heating temperature may be 80 to 100 ° C., preferably 95 to 100 ° C. What is necessary is just to set the time which heat-activates enzyme activity reliably as heat processing time, for example, it shall be about 0.5 to 10 minutes. The heat treatment is performed with a rotatable cylinder or steamer, but is not limited thereto.

The idea process is a process performed to move moisture so as to be uniformly dried and to facilitate extraction of the anti- type I allergic agent from the fig leaf. For example, the astringency process is carried out for 25 to 40 minutes while the tea leaf temperature is 35 to 60 ° C. It is considered that the moisture content of the fig leaf is about 13 to 30% by the careful process.

  Drying is performed to increase the shelf life of the fig leaf. Preferably, the fig leaf is dried so that the moisture content is 4-5%. A drying process performs the process dried at 55-65 degreeC for 2 to 5 hours, for example.

  In the above-described method for producing anti-allergic leaves, when obtaining the anti-allergic leaves, the fig leaves immediately after collection may be used, or the fig leaves stored under predetermined conditions may be used. The storage may be performed, for example, by performing low-temperature storage processing in which fig leaves are packaged in a resin film bag and stored at a low temperature for a predetermined period. The resin film bag is, for example, a low-density polyethylene bag having a thickness of about 0.02 to 0.04 mm, the temperature condition is, for example, about 0-8 ° C., and the predetermined period is, for example, 10 days or more.

The organic solvent that can be used as the extraction solvent is preferably an alcohol or a hydrous alcohol. The alcohol may be a linear or branched saturated alcohol having 1 to 8 carbon atoms, preferably 1 to 4 carbon atoms. Specifically, methanol, ethanol, n-butanol, etc. are mentioned, for example, Among these, methanol and ethanol are preferable.
The alcohol concentration of the hydrous alcohol is 20 to 80% by weight, preferably 50 to 75% by weight. For example, a hydrous alcohol having an alcohol concentration of 50% by weight refers to a mixture in which 50 parts by weight of alcohol and 50 parts by weight of water are separately weighed and mixed together in one container.

  The temperature at the time of extraction when either alcohol or hydrous alcohol is used is usually room temperature to 90 ° C, preferably 50 to 80 ° C. More preferably, the temperature is such that the hydrous alcohol is refluxed at normal pressure. At this time, the extractor may be an open system or a closed system. The extraction time is usually 0.5 to 10 hours, preferably 1 to 4 hours, although it depends on the raw materials and the extraction temperature.

For example, when extracting with a hydrous alcohol, it can manufacture by the following methods.
That is, a pulverization process for pulverizing fig leaves, a solvent addition process for adding hydrous alcohol, a shaking process for shaking after adding a solvent, and a recovery process for collecting the supernatant by centrifugation after the shaking process are performed.

  The pulverization is performed using a pulverizer capable of pulverizing freeze-dried fig leaves. In the solvent addition treatment, an appropriate amount of water-containing alcohol as an extraction solvent is added to the crushed fig leaf. In the shaking treatment, for example, shaking is performed in a circular motion at 120 rpm for 3 hours at room temperature. In the collection process, for example, the supernatant is collected by centrifuging at 12,000 rpm for 10 minutes. You may repeat a solvent addition process, a shaking process, and a collection process with respect to the residue after collect | recovering supernatants as needed.

As described above, the anti- type I allergy active ingredient is extracted using hot water or an organic solvent, for example, concentrated or diluted / dried as it is in the state where insoluble matters are mixed, or in the state where insoluble matters are removed. It is possible to perform appropriate processing such as.

The anti- type I allergy agent of the present invention means one containing an anti- type I allergy active ingredient. That is, the anti- type I allergic agent can be used in the form of a pharmaceutical such as a solid preparation or a liquid preparation, or can be used in the form of a food or drink. When used in the form of a pharmaceutical, a pharmaceutically acceptable pharmaceutical additive may be added to the active ingredient.

  When producing solid preparations such as tablets, powders and granules, pharmaceutical additives include excipients (eg, sugars, starches, celluloses, magnesium aluminate metasilicate, calcium phosphate, etc.), lubricants (eg, Magnesium stearate, talc, polyethylene glycol, etc.), binders (eg mannitol, sugars, crystalline cellulose, polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.), disintegrants (eg starches, celluloses, crosslinked polyvinylpyrrolidone, etc.), colorants, A flavoring agent or the like can be used.

  Liquid formulations can be provided, for example, in the form of aqueous or oily suspensions, solutions, emulsions, syrups or elixirs. Pharmaceutical additives used in the production of liquid preparations include solvents (for example, oil-based solvents and hydrophilic solvents), solubilizing agents (for example, polyethylene glycol and cholesterol), emulsifiers (for example, surfactants), and suspending agents. (Polyvinyl compounds, hydrophilic polymers, surfactants, etc.), preservatives (eg, parabens, sorbic acid, etc.), colorants, flavoring agents, and the like can be used.

When the anti- type I allergic agent of the present invention is used in the form of a medicine, it is configured to contain a therapeutically effective amount of an anti- type I allergy active ingredient in order to alleviate / suppress / prevent allergic symptoms. The anti- type I allergic agent thus prepared is administered to humans and animals that are subjects for alleviating, suppressing, or preventing allergic symptoms. Administration is, for example, oral administration using oral preparations such as powders, fine granules, granules, tablets, capsules, suspensions, emulsions, syrups, extracts, pills, injections, liquids for external use -It can be performed by parenteral administration using parenterals such as ointments, suppositories, eye drops and the like.

In addition to anti- type I allergy active ingredients, oral preparations include, for example, sodium alginate, starch, corn starch, sucrose, lactose, glucose, mannitol, carboxymethylcellulose, dextrin, polyvinylpyrrolidone, crystalline cellulose, soybean lecithin, sucrose, fatty acid ester, Excipients such as talc, magnesium stearate, polyethylene glycol, magnesium silicate, anhydrous silicic acid, or synthetic aluminum silicate, binders, disintegrants, surfactants, lubricants, fluidity promoters, diluents, Preservatives, colorants, fragrances, flavoring agents, stabilizers, humectants, preservatives, antioxidants, and the like can be included. That is, the oral preparation is an anti- type I allergy agent containing an anti- type I allergy active ingredient.

In addition to the anti- type I allergy active ingredient, parenteral preparations include, for example, water-soluble solvents such as physiological saline or Ringer's solution, water-insoluble solvents such as vegetable oil or fatty acid esters, isotonic agents such as glucose or sodium chloride, Solubilizing agents, stabilizers, preservatives, suspending agents, emulsifiers and the like can be included. That is, the parenteral agent is an anti- type I allergy agent containing an anti- type I allergy active ingredient.

When used in the form of food or drink, it can be provided in the form of food or drink as health food (preferably functional food) or feed. Examples of the food and drink include confectionery, soft drinks, teas, nutritional drinks, and soups. In the production process of these foods and drinks, or to the final product, an anti- I-type allergic active ingredient can be added by mixing, coating, spraying, etc. to obtain a health food. Even when used in the form of foods and drinks, in order to alleviate / suppress / prevent allergic symptoms, it is preferable to contain a therapeutically effective amount of an anti- type I allergy active ingredient.

The dosage in the case of using the anti- type I allergic agent of the present invention can be appropriately determined according to the type of allergy, age / sex / weight / symptom of the subject of administration, administration method and the like.
The anti- type I allergy agent of the present invention may contain not only anti- type I allergy active ingredients extracted from fig plants, but also anti- type I allergy active ingredients extracted from other plants.

Since the anti- type I allergic agent of the present invention can be used as an anti- type I allergic agent containing a plant-derived component as an anti- type I allergy active ingredient, it is highly safe and is continuously used as a medicine and food and drink. Can be used for

[Example 1]
Whether or not the extract extracted from the fig leaf has an antiallergic action was examined by an experiment using cultured cells. As the fig leaf, a commercially available fig tea “凜 雫” (manufactured by Suwa-en, sold by Kawanishi City Chamber of Commerce and Industry) was used. In addition, “Benifuuki green tea” (manufactured by Mikasaen Co., Ltd., Shinya Tea Co., Ltd.), which is known to have an antiallergic action, was used as a positive control. The raw material variety of the fig tea is Sakurai Dauphin.
The tea leaves were prepared and the tea extract was prepared in accordance with the above-described heat treatment / relief treatment / drying treatment / extraction treatment. In the extraction process, 100 mL of ultrapure water (temperature: 80 ° C.) was added per 1 g of each tea leaf, left to stand for 3 minutes, and then filtered through a 0.45 mm membrane filter to prepare a tea extract.

The cultured cells used were the peripheral blood-derived mast cell line RBL-2H3 (JCRB0023) of basophilic leukemia rats. The amount of β-hexosaminidase (β-Hex) released simultaneously with the inflammatory substance histamine during degranulation of the cells was measured and used as an indicator of degranulation. The culture medium is Earle's minimal essential medium medium (containing 10% calf serum (FBS), 100unit / ml penicillin, 100mg / ml streptomycin). The culture conditions are static at 37 ° C and 5% CO ₂ concentration. Incubated.

Cells (final concentration: 2 × 10 ⁵ cells / well) suspended in 400 μL of culture solution are seeded in a 24-well culture plate, and after static culture at 37 ° C. and 5% CO ₂ concentration for 1 hour, 1/10 An amount of tea extract (1 mg / mL in terms of final concentration tea leaves) was added. Further, as a negative control (control), phosphate buffered saline (calcium chloride and magnesium chloride are not included. Hereinafter, PBS (-) is referred to) was added.
Then, mouse monoclonal anti-DNP-IgE antibody was added at a final concentration of 0.45 mg / mL, and the cells were cultured for 24 hours at 37 ° C. under CO ₂ concentration of 5% to sensitize the cells. Thereafter, the culture solution is removed, washed with a PBS (−) solution, and 160 μL of a reaction buffer solution (137 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl ₂ , 1 mM MgCl ₂ , 5.6 mM glucose, 20 mM HEPES, 0 0.1% BSA, pH 6.8) was added. Therefore, the tea extract is not included in the subsequent steps.
DNP-BSA as an antigen was added to a final concentration of 10 μg / mL, and an antigen-antibody reaction was performed at 37 ° C. for 30 minutes to induce degranulation. After leaving the plate on ice for 10 minutes to stop the reaction, 50 μL of the buffer supernatant was collected in a 96-well plate and dissolved in β-Hex substrate solution (0.1 M citrate buffer pH 4.5). 1 mM p-nitrophenyl-N-acetyl-bD-glucosaminide) was added in an equal amount and reacted at 37 ° C. for 1 hour.
0.1 M carbonate-bicarbonate buffer (pH 10.4) was added to stop the enzymatic reaction and perform a color reaction, and the absorbance at 405 nm was measured.

The evaluation results of the antiallergic action are shown in FIG.
When the release amount of β-Hex in the cell line to which PBS (−) as a control was added was taken as 100%, the release amount of β-Hex when fig tea (Example 1) was added at the time of sensitization was about 35%. The amount of β-Hex released when Benifukuuki green tea (Comparative Example 1) was added during sensitization was about 41%. In this way, in the cell lines to which fig tea and Benifuku green tea were added, the amount of β-Hex released was suppressed to about 40%, so the amount of the inflammatory substance histamine released at the time of degranulation was equally suppressed. It was recognized that Therefore, it was found that the fig tea contains a substance (anti- type I allergy active ingredient) that suppresses the release (degranulation) of the chemical mediator in the immune reaction. Furthermore, fig tea was found to have an antiallergic effect equivalent to Benifuuki green tea. In this example, the tea extract is included only during sensitization and not during subsequent antigen-antibody reaction or degranulation. Thus, it was found that the fig tea extract inhibits sensitization of cells and as a result, degranulation is inhibited.

[Example 2]
In five varieties of figs, the degree of anti-allergic activity of the extract extracted from each tea leaf was examined by experiments using cultured cells. The fig cultivars are: Sakurai Dauphin (Example 2-1), Temari Fig (Example 2-2), Dalmaty (Example 2-3), Precos Ronde de Bordeaux (Example 2-4) Negrone (Example 2-5) was used. Tea leaves were prepared as follows.
In addition, the fig tea of Example 1 is the same cultivar (Sakurai Dauphin) as the fig tea of Example 2-1. The fig tea of Example 1 is a commercial product, and the fig tea of Example 2-1 is the inventors' own work.

(1) The fig leaf collected the young leaf near the tip of a new treetop.
(2) Leaves chopped into approximately 2 cm squares were put into a colander and boiled for 4 minutes at 95-100 ° C. with steam (heat treatment).
(3) Kraft paper was laid on the hot plate top plate, and steamed leaves were transferred onto it. While heating the leaves to about 35-60, the leaves were twisted manually on the hot plate for about 30 minutes (relief process).
(4) The leaves after the twisting treatment were put in a colander, placed in a blower dryer and dried at 60 ° C. for 4 hours (drying treatment).
(5) Immediately after drying, it was hermetically packaged in a resin film bag laminated with an aluminum foil and stored frozen.

  The method for preparing the tea extract, the type of cultured cells, the culture conditions, and the method for evaluating the antiallergic action were performed according to Example 1.

The evaluation results of the antiallergic action of the five varieties of fig tea are shown in FIG.
When the release amount of β-Hex in the cell line to which PBS (−) as a control was added was defined as 100%, in the five varieties of fig tea (Examples 2-1 to 2-5), the release amount of β-Hex Was about 30 to 40%. As a result, in the cell lines to which the five varieties of fig tea were added, the amount of β-Hex released was suppressed to about 30 to 40%, and thus the amount of the inflammatory substance histamine released during degranulation was equally suppressed. It was accepted. Therefore, it is suggested that the plants of the genus Fig include universally substances that suppress excessive chemical mediator release (degranulation) by suppressing sensitization (anti- type I allergy active ingredient). .
In addition, it was recognized that the self-made fig tea (Example 2-1) and the commercially available fig tea (Example 1) having the same cultivar had almost the same antiallergic effect. From this, it was speculated that the anti- type I allergic agent containing the anti- type I allergy active ingredient of the present invention is not affected by differences in apparatus, temperature conditions, etc. in fig tea production. Therefore, there is no need strict condition setting is in making the anti-type I allergy agents, the production of anti-type I antiallergic agent is easy.

Example 3
Fig tea produced from commercially available fig tea was fractionated by preparative HPLC (hereinafter, preparative LC) at each elution time, and the antiallergic action in each fraction was measured. The fig tea was prepared and each fraction was collected as follows.

(1) Add 100 mL of ultrapure water (temperature 80 ° C.) per 3 g of tea leaves of commercially available fig tea (Kawanishi-shi fig tea “凜 雫”), let stand for 3 minutes, and then filter with a 0.45 mm membrane filter to make tea An extract was prepared.
(2) The adjusted extract was concentrated under reduced pressure using a rotary evaporator.
(3) After further freezing in a freezer, it was processed with a freeze dryer for about 24 hours to obtain a dried product.
(4) 4 mL of ultrapure water (room temperature) was added to the dried product to dissolve it, and filtered through a 0.2 mm membrane filter to obtain a tea extract concentrate.
(5) 200 μL of the tea extract concentrate was injected into a preparative LC device Delta 600 system (manufactured by Waters), and fractions were collected by a fraction collector until 90 minutes after every 10 minutes of elution time.
(6) The collected fractions were concentrated under reduced pressure using a rotary evaporator.
(7) After further freezing in a freezer, it was processed with a freeze dryer for about 24 hours to obtain a dried product.
(8) 1 mL of ultrapure water (room temperature) was added to the dried product and dissolved to obtain each fraction solution (fractions 1 to 9).
The collection conditions of the fractions are as follows.

  About each of the collect | recovered fractions 1-9, the antiallergic action was measured using the cultured cell. The types of cultured cells and the culture conditions were the same as in Example 1. The evaluation method of the antiallergic action was performed according to Example 1 except that the amount of the fraction solution added to the cell culture solution was set to 1/100 of the method described in Example 1.

  The evaluation results of the antiallergic action are shown in FIG. The amount of β-Hex released in fraction 1 was about 47% when the amount of β-Hex released in the cell line added with PBS (−) as a control was taken as 100%. In fractions 2 to 9, the amount of β-Hex released was 70% or more. That is, the strongest antiallergic action was observed in fraction 1. This suggests that fraction 1 contains a substance having a strong antiallergic action (antiallergic substance) or contains a lot of substances having an antiallergic action. Further, in the preparative LC performed in this example, since a reverse phase gradient condition using an ODS column is used, a substance having a higher polarity elutes earlier. From this, since fraction 1 is the fraction with the earliest elution time, the antiallergic substance is considered to be a highly polar component.

The fig-derived anti- type I allergic agent and the method for producing the same of the present invention can be used to alleviate / suppress / prevent allergic symptoms.

A Heat treatment B Care process C Dry process D Extraction process

Claims (6)

From fig leaves, water, hot water, anti-type I allergy agent comprising as an anti-type I allergy effective ingredient to type I allergy extracted component extracted by either extraction solvent alcohol or water-containing alcohol. Heat treatment of steaming the fig leaf with steam at 95 ° C-100 ° C for 0.5-10 minutes,
An astringent treatment in which the fig leaves subjected to the heat treatment are abandoned for 25 to 40 minutes in a state where the tea leaf temperature is 35 to 60 ° C.,
A drying treatment for drying the fig leaf that has been subjected to the idea treatment at 55 to 65 ° C. for 2 to 5 hours,
Anti type I according to claim 1 containing the dried extract components extracted at a temperature of 80 to 100 ° C. in a hot water by adding 1 atm is fig leaves the extraction solvent as an anti-type I allergy active ingredient Allergic agent. The anti- I-type allergic agent according to claim 1 or 2 , wherein the fig cultivar is any one of Sakurai Dauphin, Temari fig, Dalmaty, Precos Ronde de Bordeaux and Negrone. The anti- type I allergy agent according to any one of claims 1 to 3 , wherein the anti- type I allergy active ingredient is formulated in the form of a solid preparation or a liquid preparation. Heat treatment to steam the fig leaf,
An ambush process for waking up the fig leaf that has been subjected to the heat treatment,
A drying process for drying the fig leaf that has undergone the above-mentioned conception process;
A method for producing an anti- type I allergy agent, wherein hot water as an extraction solvent is added to the dried fig leaf and an extraction process is carried out to obtain an extract composition containing an anti- type I allergy active ingredient against type I allergy. The heat treatment is performed with steam at 95 ° C. to 100 ° C. for 0.5 to 10 minutes, the careful treatment is performed for 25 to 40 minutes with the tea leaf temperature being 35 to 60 ° C., and the drying treatment is 55 to 65 ° C. The method for producing an anti- type I allergic agent according to claim 5 , wherein the extraction treatment is performed at a pressure of 80 to 100 ° C at 1 atmosphere.

Images